Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Working Capital Changes (2016 - 2025)

Voyager Therapeutics' Other Working Capital Changes history spans 11 years, with the latest figure at $11.1 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 157.13% year-over-year to $11.1 million; the TTM value through Dec 2025 reached -$7.2 million, down 375.1%, while the annual FY2025 figure was -$7.2 million, 375.1% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was $11.1 million at Voyager Therapeutics, up from -$20.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $53.3 million in Q1 2022 and bottomed at -$51.1 million in Q3 2022.
  • The 5-year median for Other Working Capital Changes is $245500.0 (2021), against an average of -$871550.0.
  • The largest annual shift saw Other Working Capital Changes soared 16616.1% in 2022 before it crashed 138734.62% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at $465000.0 in 2021, then plummeted by 1298.71% to -$5.6 million in 2022, then surged by 262.76% to $9.1 million in 2023, then crashed by 52.33% to $4.3 million in 2024, then soared by 157.13% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Other Working Capital Changes are $11.1 million (Q4 2025), -$20.2 million (Q3 2025), and $3.6 million (Q2 2025).